Bicocca Open Archive

Logo unimib boa
POGLIANI, ENRICO MARIA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 9.100
EU - Europa 3.967
AS - Asia 1.826
SA - Sud America 70
Continente sconosciuto - Info sul continente non disponibili 15
AF - Africa 10
OC - Oceania 7
Totale 14.995
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 8.918
DE - Germania 731
CN - Cina 676
SE - Svezia 616
IE - Irlanda 611
SG - Singapore 603
UA - Ucraina 534
IT - Italia 464
RU - Federazione Russa 463
HK - Hong Kong 372
GB - Regno Unito 192
CA - Canada 175
FI - Finlandia 124
BR - Brasile 61
FR - Francia 59
IN - India 57
NL - Olanda 37
DK - Danimarca 34
AT - Austria 32
VN - Vietnam 30
BE - Belgio 28
JP - Giappone 23
TR - Turchia 23
EU - Europa 14
ID - Indonesia 8
ES - Italia 7
AU - Australia 6
RO - Romania 6
AR - Argentina 5
CZ - Repubblica Ceca 5
BG - Bulgaria 4
IR - Iran 4
KR - Corea 4
PL - Polonia 4
SA - Arabia Saudita 4
EG - Egitto 3
HU - Ungheria 3
IQ - Iraq 3
LT - Lituania 3
TH - Thailandia 3
AZ - Azerbaigian 2
BD - Bangladesh 2
EC - Ecuador 2
KE - Kenya 2
MA - Marocco 2
MK - Macedonia 2
MX - Messico 2
PA - Panama 2
PT - Portogallo 2
TW - Taiwan 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AE - Emirati Arabi Uniti 1
AL - Albania 1
AM - Armenia 1
CH - Svizzera 1
CO - Colombia 1
CR - Costa Rica 1
CU - Cuba 1
DO - Repubblica Dominicana 1
EE - Estonia 1
GE - Georgia 1
HR - Croazia 1
KG - Kirghizistan 1
LB - Libano 1
LK - Sri Lanka 1
MD - Moldavia 1
MU - Mauritius 1
MZ - Mozambico 1
NO - Norvegia 1
NP - Nepal 1
NZ - Nuova Zelanda 1
PH - Filippine 1
PK - Pakistan 1
SR - Suriname 1
TN - Tunisia 1
UZ - Uzbekistan 1
Totale 14.995
Salva come PNG Salva come JPEG
Città #
Ann Arbor 1.839
Woodbridge 1.038
Houston 740
Fairfield 647
Dublin 599
Jacksonville 588
Ashburn 457
Chandler 457
Frankfurt am Main 379
Hong Kong 372
Wilmington 367
Singapore 357
Dearborn 323
Seattle 252
New York 238
Princeton 224
Cambridge 207
Milan 142
Nanjing 127
Santa Clara 124
Shanghai 113
Lawrence 103
Lachine 102
Altamura 100
Beijing 93
Göttingen 52
Nanchang 42
Andover 37
Moscow 37
Toronto 33
Guangzhou 32
Shenyang 32
Changsha 31
San Diego 31
Ottawa 29
Brussels 28
Hebei 28
Los Angeles 27
Vienna 27
Boardman 22
Huizen 22
Helsinki 21
Fürstenwalde 18
London 18
Fremont 17
Jiaxing 17
Lissone 16
Norwalk 16
Redmond 16
Council Bluffs 15
Hefei 15
Nürnberg 15
University Park 15
Hangzhou 14
Jinan 14
Pune 14
Tianjin 14
Chicago 13
Kunming 13
Mountain View 13
Rome 10
Zhengzhou 10
Falls Church 9
Romola 9
Auburn Hills 8
Dong Ket 8
Edmonton 8
Buffalo 7
Munich 7
Bologna 6
Brescia 6
Dallas 6
San Mateo 6
Washington 6
Jakarta 5
Leawood 5
Mumbai 5
Omegna 5
Taizhou 5
Bari 4
Chelsea 4
Gorgonzola 4
Haikou 4
Jeddah 4
Kiev 4
Kilburn 4
Kocaeli 4
Madrid 4
Nuremberg 4
Plovdiv 4
Simi Valley 4
Tokyo 4
Bengaluru 3
Bonndorf 3
Campinas 3
Chongqing 3
Cinisello Balsamo 3
Clifton 3
Cutrofiano 3
Desio 3
Totale 10.999
Salva come PNG Salva come JPEG
Nome #
Increased tissue factor pathway inhibitor and homocysteine in Alzheimer's disease 404
A randomized clinical trial of ceftriaxone and amikacin versus piperacillin tazobactam and amikacin in febrile patients with hematological neoplasia and severe neutropenia 383
Treatment of Graft versus Host Disease with Mesenchymal Stromal Cells: A Phase I Study on 40 Adult and Pediatric Patients 335
Imatinib Long-Term Effects Study: Global Independent Assessment of Imatinib in Chronic Myeloid Leukemia: Results At 8 Years 321
Multicenter Independent Assessment of Outcomes in Chronic Myeloid Leukemia Patients Treated With Imatinib 314
Imatinib long term effects study: three years of follow-up and assessment 274
Safe and Effective Treatment of Graft Versus Host Disease with Platelet Lysate-Expanded Human Mesenchymal Stromal Cells: A Phase 1 Study On 47 Adult and Pediatric Patients 265
A boost of CD34+-selected peripheral blood cells without further conditioning in patients with poor graft function following allogeneic stem cell transplantation 252
GMP-grade preparation of biomimetic scaffolds with osteo-differentiated autologous mesenchymal stromal cells for the treatment of alveolar bone resorption in periodontal disease 244
Recurrent SETBP1 mutations in atypical chronic myeloid leukemia 235
Thrombosis of the splenoportal axis after splenectomy 207
Repeated infusions of donor-derived cytokine-induced killer cells in patients relapsing after allogeneic stem cell transplantation: A phase I study 207
Inhibition of the ABL kinase activity blocks the proliferation of BCR/ABL+ leukemic cells and induces apoptosis 200
Good outcome for very high risk adult B-cell acute lymphoblastic leukaemia carrying genetic abnormalities t(4;11)(q21;q23) or t(9;22)(q34;q11), if promptly submitted to allogeneic transplantation, after obtaining a good molecular remission 199
A prospective study on cardiovascular events after acute pulmonary embolism 193
A CASE OF ATYPICAL PROLONGED HEMATOLOGIC TOXICITY WITH AZACITIDINE IN CHRONIC MYELOMONOCYTIC LEUKEMIA (CMML), REVIEW OF LITERATURE AND A PROPOSAL OF MANAGEMENT 193
Development of polycythemia vera after chemotherapy-induced remission of acute myeloid leukemia: a case report 184
CML Patients Present Additional Mutations in Cancer Related Genes When Tested At Diagnosis 182
The achievement of durable complete cytogenetic remission in late chronic and accelerated phase patients with CML treated with Imatinib mesylate predicts for prolonged response at 6 years 174
Severe, reversible nelarabine-induced neuropathy and myelopathy 174
Rituximab prevents recurrence of thrombotic thrombocytopenic purpura: A case report 173
BCR AND BCR-ABL REGULATION DURING MYELOID DIFFERENTIATION IN HEALTHY DONORS AND CHRONIC PHASE-BLAST CRISIS CML PATIENTS 173
Circulating endothelial cells and endothelial activation in essential thrombocythemia: Results from CD146(+) immunomagnetic enrichment-flow cytometry and soluble E-selectin detection 173
Long-term follow-up of patients with intermediate or high-grade non-Hodgkin lymphoma treated with a combination of cyclophosphamide, epirubicin, vincristine, and prednisone 170
Recurrent SETBP1 Mutations in Atypical Chronic Myeloid Leukemia 167
BCR and BCR-ABL regulation during myeloid differentiation in healthy donors and in chronic phase/blast crisis CML patients 165
Results of a lymphoblastic leukemia-like chemotherapy program with risk-adapted mediastinal irradiation and stem cell transplantation for adult patients with lymphoblastic lymphoma 162
Autoimmune hepatitis presenting as imatinib toxicity: description of a case and of therapeutic alternatives 162
A randomized comparison of caspofungin versus antifungal prophylaxis according to investigator policy in acute leukaemia patients undergoing induction chemotherapy (PROFIL-C study) 156
NPM/ALK binds and phosphorylates the RNA/DNA binding protein PSF in anaplastic large cell lymphoma 156
Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma 155
Mechanisms of resistance to imatinib in chronic myeloid leukemia (CML) patients in chronic phase (CP) who achieved durable complete cytogenetic responses (CCR) 155
Combined prophylactic low-molecular weight heparin and low dose aspirin reduces the occurrences of adverse pregnancy outcome in multiparous women with preeclampsia and intrauterine fetal growth restriction in antecedent pregnancy 153
Recurrent preeclapsia: The role of acquired and heritable thrombophilia 153
CD20 expression has no prognostic role in Philadelphia-negative B-precursor acute lymphoblastic leukemia: new insights from the molecular study of minimal residual disease 153
AIDA 0493 protocol for newly diagnosed acute promyelocytic leukemia: very long-term results and role of maintenance 152
Role of radiotherapy in patients with early-stage diffuse large B-cell lymphoma of Waldeyer's ring in remission after anthracycline-containing chemotherapy 150
Platelet activation during plasma-reduced multicomponent PLT collection: A comparison between COBE Trima and Spectra LRS turbo cell separators 148
Imatinib dose increase up to 1200 mg daily can induce new durable complete cytogenetic remissions in relapsed Ph+ chronic myeloid leukemia patients 148
Demographic and clinical data in acquired hemophilia A: results from the European Acquired Haemophilia Registry (EACH2) 144
Extracorporeal photochemotherapy for the treatment of chronic graft-versus-host disease: trend for a possible cell dose-related effect? 143
Crizotinib in anaplastic large-cell lymphoma 143
Intermediate-dose melphalan improves survival of myeloma patients aged 50 to 70: results of a randomized controlled trial 142
High response rate and improvement of long-term survival with combined treatment modalities in patients with poor-risk primary thyroid diffuse large B-cell lymphoma: an International Extranodal Lymphoma Study Group and Intergruppo Italiano Linfomi study 142
Hydroxyurea-related toxicity in 3,411 patients with Ph'-negative MPN 140
Management of bleeding in acquired hemophilia A: results from the European Acquired Haemophilia (EACH2) Registry 138
Second malignancy after treatment of adult acute myeloid leukemia: cohort study on adult patients enrolled in the GIMEMA trials 138
Imatinib failed to eradicate chronic myeloid leukemia in a patient with minimal residual disease 137
High versus standard dose methylprednisolone in the acute phase of idiopathic thrombotic thrombocytopenic purpura: A randomized study 134
Prevention of venous thromboembolism in immobilized neurological patients: Guidelines of the Italian Society for Haemostasis and Thrombosis (SISET) 134
Increased risk of recurrent thrombosis in patients with essential thrombocythemia carrying the homozygous JAK2 V617F mutation 133
Complement activation: the missing link between ADAMTS-13 deficiency and microvascular thrombosis of thrombotic microangiopathies 130
Final results of a multicenter trial addressing role of CSF flow cytometric analysis in NHL patients at high risk for CNS dissemination 129
ABVD versus BEACOPP for Hodgkin's lymphoma when high-dose salvage is planned 127
HOMOZYGOSITY FOR JAK2V617F IDENTIFIES MPD PATIENTS WITH A MORE SYMPTOMATIC DISEASE A RETROSPECTIVE STUDY ON 989 PATIENTS FROM THE GIMEMA-MPD WORKING PARTY 126
Rituximab as pre-emptive treatment in patients with thrombotic thrombocytopenic purpura and evidence of anti-ADAMTS13 autoantibodies 125
Front-line treatment of acute promyelocytic leukemia with AIDA induction followed by risk-adapted consolidation for adults younger than 61 years: results of the AIDA-2000 trial of the GIMEMA Group 124
Neurological symptoms in essential thrombocythemia: Impact of JAK2V617F mutation and response to therapy 122
Resistance Profile of the BCR/ABL Inhibitor Bosutinib Using a High Throughput random Mutagenesis Assay 121
Development of c-Kit-expressing Small-Cell lung Cancer in a Chronic Myeloid Leukemia Patient During Imatinib Treatment 119
Gemtuzumab ozogamicin (Mylotarg) as a single agent for molecularly relapsed acute promyelocytic leukemia 118
Chemotherapy-phased imatinib pulses improve long-term outcome of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: Northern Italy Leukemia Group protocol 09/00 118
A case of Philadelphia Positive Acute Lymphoblastic Leukaemia with three different phenotypic lineage, each one presenting the same BCR-ABL hybrid transcript 116
From Vaquez to Dameshek through JAK…2 much for polycythemia vera to be feared? 116
Frozen-and-thawed allogeneic platelet gels for treating postoperative chronic wounds 113
Venous thromboembolism and cancer: Guidelines of the Italian Association of Medical Oncology (AIOM) 112
Improved risk classification for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL) 112
Antithrombotic prophylaxis in multiparous women with preeclampsia or intrauterine growth retardation in an antecedent pregnancy 111
Fully immunocompetent CD8+ T lymphocytes are present in autologous haematopoietic stem cell transplantation recipients despite an ineffectual T-helper response 111
SIGNIFICANT REDUCTION IN FASTING BLOOD GLUCOSE IN NONDIABETIC PH+ CHRONIC MYELOID LEUKEMIA PATIENTS TREATED WITH IMATINIB MESYLATE 111
CLIPI: a new prognostic index for indolent cutaneous B cell lymphoma proposed by the International Extranodal Lymphoma Study Group (IELSG 11) 108
Cytarabine and clofarabine after high-dose cytarabine in relapsed or refractory AML patients 107
Valproic acid at therapeutic plasma levels may increase 5-azacytidine efficacy in higher risk myelodysplastic syndromes 105
Reviewed diagnosis of primary and secondary immune thrombocytopenic purpura in 79 adult patients hospitalized in 2000-2002 104
Incidence of thrombotic complications in patients with haematological malignancies with central venous catheters: A prospective multicentre study 103
Cytomegalovirus infection after autologous stem cell transplantation: incidence and outcome in a group of patients undergoing a surveillance program 102
Role of BCL2L10 methylation and TET2 mutations in higher risk myelodysplastic syndromes treated with 5-azacytidine 101
Management of poor peripheral blood stem cell mobilization: Incidence, predictive factors, alternative strategies and outcome. A retrospective analysis on 2177 patients from three major Italian institutions 100
Immunoglobulin M monoclonal gammopathies of undetermined significance and indolent Waldenström's macroglobulinemia recognize the same determinants of evolution into symptomatic lymphoid disorders: Proposal for a common prognostic scoring system 99
Allogeneic transplantation following a reduced-intensity conditioning regimen in relapsed/refractory peripheral T-cell lymphomas: long-term remissions and response to donor lymphocyte infusions support the role of a graft-versus-lymphoma effect 94
Peg-filgrastim versus filgrastim after autologous stem cell tranplantation: case-control study in patients with multiple myeloma and review of the literature 93
Corticosteroids can reverse severe imatinib-induced hepatotoxicity 90
Analysis of the host pharmacogenetic background for prediction of outcome and toxicity in diffuse large B-cell lymphoma treated with R-CHOP21 88
Transplant-finalized salvage of adult acute lymphoblastic leukemia: results of a mitoxantrone- and methotrexate-based regimen in 36 patients 87
Iron chelation therapy with deferasirox in the management of iron overload in primary myelofibrosis 87
The host genetic background of DNA repair mechanisms is an independent predictor of survival in diffuse large B-cell lymphoma 85
Extracorporeal photopheresis for the treatment of steroid refractory acute GVHD 85
Advanced mast cell disease: an Italian Hematological Multicenter experience 85
Leukocytosis is a risk factor for recurrent arterial thrombosis in young patients with polycythemia vera and essential thrombocythemia 85
Primary plasma cell leukemia: a retrospective multicenter study of 73 patients 85
In reply to 'Cardiotoxicity of the cancer therapeutic agent imatinib mesylate' [2] 82
Imatinib concentrations in human milk 82
Prospective, multicenter randomized GITMO/IIL trial comparing intensive (R-HDS) versus conventional (CHOP-R) chemoimmunotherapy in high-risk follicular lymphoma at diagnosis: the superior disease control of R-HDS does not translate into an overall survival advantage 81
Peripheral blood progenitor cell collection in chronic myeloid leukemia patients with complete cytogenetic response after treatment with imatinib mesylate 79
Recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia: Incidence, risk factors, and effect of treatments 79
Allogeneic stem cell transplantation following reduced-intensity conditioning can induce durable clinical and molecular remissions in relapsed lymphomas: pre-transplant disease status and histotype heavily influence outcome 79
Acute leukemia in polycythemia vera: an analysis of 1638 patients enrolled in a prospective observational study 78
Mast cell leukemia: A report of ten cases 76
Quality of life in elderly patients with essential thrombocythaemia. An Italian multicentre study 75
Low Efficiency of a Newly Introduced High-Density Microparticles Method for B Cell Depletion in Multiple Myeloma Patients Undergoing Autologous Hematopoietic Stem Cell Transplantation 74
Totale 14.571
Salva come PNG Salva come JPEG
Categoria #
all - tutte 59.309
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 59.309
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020375 0 0 0 0 0 0 0 0 0 136 197 42
2020/20211.660 134 84 238 214 107 108 168 100 176 180 66 85
2021/20221.088 50 58 90 111 85 103 42 85 71 92 106 195
2022/20232.038 293 671 195 163 127 311 17 79 109 6 34 33
2023/20241.665 38 45 54 78 244 490 341 47 174 13 21 120
2024/20251.864 211 356 120 138 296 75 122 75 319 152 0 0
Totale 15.317